Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, Taubert H, Wullich B, Weyerer V, Stöhr R, Zengerling F, Bolenz C, Breyer J, Burger M, Porubsky S, Hartmann A, Erben P, Eckstein M, Juette H (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Barcelona ES

DOI: 10.1093/annonc/mdz249.032

Authors with CRIS profile

Helge Taubert Professur für Molekulare Urologie Bernd Wullich Lehrstuhl für Urologie Veronika Bahlinger Institute of Pathology Robert Stöhr Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Markus Eckstein Institute of Pathology

Involved external institutions

Ruhr-Universität Bochum (RUB) DE Germany (DE) Universität Regensburg DE Germany (DE) STRATIFYER Molecular Pathology GmbH DE Germany (DE) Universität Ulm DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE)

How to cite

APA:

Roghmann, F., Wirtz, R., Jarczyk, J., Kriegmair, M.C., Worst, T.S., Sikic, D.,... Juette, H. (2019). Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting. In ANNALS OF ONCOLOGY. Barcelona, ES: OXFORD: OXFORD UNIV PRESS.

MLA:

Roghmann, F., et al. "Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019.

BibTeX: Download